News & Updates

Treatment with teplizumab significantly preserved beta(ß)-cell function, as measured by C-peptide levels, in children and adolescents with new-onset type 1 diabetes (T1D) compared with placebo, according to the PROTECT* study.

New drug applications approved by US FDA as of 16-30 November  2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Initiating antiretroviral therapy (ART) within 48 hours of life for infants born with HIV can lead to sustained viral suppression, as reflected by reduced HIV reservoirs by age 2 years, which suggests the possibility of an ART-free remission.

Wearing soft contact lenses with extended depth of focus reduces axial elongation and, in turn, delays the progression of myopia in children when compared with using distance single-vision spectacles, as shown in a study.

The risk of colectomy in paediatric onset ulcerative colitis (UC) has significantly decreased at the population level along with an increase in the use of immunosuppressants and antitumour necrosis factor (anti-TNF), reports a study.

Maternal cannabis use during pregnancy appears to contribute to increased risk of adverse neonatal health outcomes, including low birth weight (LBW) and small for gestational age (SGA), as reported in a study.

Treatment with flexible ureteroscopy (FE) results in a significantly higher stone-free rate than shock wave lithotripsy (SWL) in children with renal stones, reports a study. No difference is seen in complication rate or fluoroscopy exposure time between groups, but operative times and hospital stay are longer with FU.

Treatment with dupilumab reduces the use of systemic corticosteroids (SCS) in children with moderate-to-severe asthma, regardless of exacerbation history, according to a post hoc analysis of the VOYAGE and EXCURSION trials presented at APSR 2023.

The respiratory system is the main target of human rhinovirus/enterovirus (HRV/EV) infections, which show a clinical course with low mortality rates, reveals a study.